- Home
- XOS vs GLTO Comparison
XOS vs GLTO Comparison
Compare XOS & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOS
- GLTO
- Stock Information
- Founded
- XOS 2016
- GLTO 2011
- Country
- XOS United States
- GLTO Denmark
- Employees
- XOS N/A
- GLTO N/A
- Industry
- XOS Construction/Ag Equipment/Trucks
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- XOS Consumer Discretionary
- GLTO Health Care
- Exchange
- XOS Nasdaq
- GLTO Nasdaq
- Market Cap
- XOS 27.8M
- GLTO 23.7M
- IPO Year
- XOS N/A
- GLTO 2020
- Fundamental
- Price
- XOS $2.40
- GLTO $5.18
- Analyst Decision
- XOS Buy
- GLTO
- Analyst Count
- XOS 2
- GLTO 0
- Target Price
- XOS $6.00
- GLTO N/A
- AVG Volume (30 Days)
- XOS 30.9K
- GLTO 99.5K
- Earning Date
- XOS 11-13-2025
- GLTO 11-06-2025
- Dividend Yield
- XOS N/A
- GLTO N/A
- EPS Growth
- XOS N/A
- GLTO N/A
- EPS
- XOS N/A
- GLTO N/A
- Revenue
- XOS $51,536,000.00
- GLTO N/A
- Revenue This Year
- XOS $2.34
- GLTO N/A
- Revenue Next Year
- XOS $27.38
- GLTO N/A
- P/E Ratio
- XOS N/A
- GLTO N/A
- Revenue Growth
- XOS N/A
- GLTO N/A
- 52 Week Low
- XOS $2.21
- GLTO $2.01
- 52 Week High
- XOS $9.15
- GLTO $31.70
- Technical
- Relative Strength Index (RSI)
- XOS 33.36
- GLTO 40.16
- Support Level
- XOS $2.60
- GLTO $7.02
- Resistance Level
- XOS $2.87
- GLTO $7.64
- Average True Range (ATR)
- XOS 0.11
- GLTO 0.58
- MACD
- XOS -0.04
- GLTO -0.54
- Stochastic Oscillator
- XOS 1.96
- GLTO 4.00
About XOS Xos Inc.
Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Classes 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.